FDA Approves Mitapivat for Thalassemia Anemia; Vadadustat Dosing Trial Meets Safety Goals
Jul 22, 2026
The FDA has approved Agios Pharmaceuticals' mitapivat (AQVESME) as the first oral treatment for anemia in thalassemia, reducing transfusion needs by 40-50%. Meanwhile, a clinical trial found a three-times-weekly dosing of vadadustat (Vafseo) is safe for kidney dialysis patients, potentially improving convenience.